SRPT | Sarepta Therapeutics, Inc. |
Pharmaceutical Preparations |
Book value per $ invested | $ 0.10 |
Leverage | 66.08% |
Market Cap | $ 12.5B |
PE | 104.66 |
Dividend Yield | 0.00% |
Profit | $ 119.6m |
Margin | 7.20% |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.